His primary areas of investigation include Immunology, Dendritic cell, Cytotoxic T cell, Antigen and Antigen-presenting cell. His research integrates issues of Cancer research, CD40, Bortezomib, Cell biology and Interleukin 10 in his study of Dendritic cell. His biological study spans a wide range of topics, including Epitope, Molecular biology, Peripheral blood mononuclear cell and Major histocompatibility complex.
The study incorporates disciplines such as Virology, Immune system, Immunotherapy, Viral replication and Antigen presentation in addition to Antigen. In the field of Immune system, his study on Lymphokine-activated killer cell overlaps with subjects such as Context. The various areas that he examines in his Antigen-presenting cell study include Endocytic cycle, Endocytosis and Internalization.
Peter Brossart mainly investigates Internal medicine, Immunology, Cancer research, Oncology and Antigen. His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Surgery. His study in Immunology concentrates on Immune system, Immunotherapy, Dendritic cell and T cell.
His Dendritic cell study combines topics in areas such as Cell biology, Monocyte and Antigen-presenting cell. His research in Cancer research intersects with topics in Apoptosis and Pathology. His study looks at the relationship between Antigen and topics such as Cytotoxic T cell, which overlap with Major histocompatibility complex.
His primary areas of investigation include Internal medicine, Oncology, Cancer research, Multiple myeloma and Nivolumab. Internal medicine connects with themes related to Gastroenterology in his study. The concepts of his Oncology study are interwoven with issues in Clinical trial, Long term results, Chemotherapy and Immunotherapy.
His Cancer research study incorporates themes from Acquired immune system, Oxidative stress, Methylation, DNA methylation and Dendritic cell. His biological study deals with issues like White blood cell, which deal with fields such as T cell and Immune system. In his study, Immunology and Cancer is strongly linked to Severe acute respiratory syndrome coronavirus 2, which falls under the umbrella field of T cell.
His primary scientific interests are in Internal medicine, Oncology, Chemotherapy, Immunotherapy and DNA methylation. His Internal medicine study frequently involves adjacent topics like Gastroenterology. His studies deal with areas such as Clinical trial, Melphalan, Lenalidomide, Multiple myeloma and Randomized controlled trial as well as Oncology.
His Chemotherapy study integrates concerns from other disciplines, such as Nivolumab, Adverse effect and Carcinoma. The DNA methylation study combines topics in areas such as Immune checkpoint, Cancer research and Methylation. Peter Brossart studies Melanoma, a branch of Cancer research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids.
Alexander Kugler;Gernot Stuhler;Peter Walden;Gerhard Zöller.
Nature Medicine (2000)
Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells.
Peter Brossart;Stefan Wirths;Gernot Stuhler;Volker L. Reichardt.
Identification of HLA-A2–Restricted T-Cell Epitopes Derived From the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies
Peter Brossart;Kathrin S. Heinrich;Gernot Stuhler;Lars Behnke.
Her-2/neu-derived Peptides Are Tumor-associated Antigens Expressed by Human Renal Cell and Colon Carcinoma Lines and Are Recognized by in Vitro Induced Specific Cytotoxic T Lymphocytes
Peter Brossart;Gernot Stuhler;Thomas Flad;Stefan Stevanovic.
Cancer Research (1998)
Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells.
Susanne M. Schmidt;Kerstin Schag;Martin R. Müller;Markus M. Weck.
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses.
Madeleine M. Hipp;Norbert Hilf;Steffen Walter;Daniela Werth.
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.
Uwe Platzbecker;Giuseppe Avvisati;Laura Cicconi;Christian Thiede.
Journal of Clinical Oncology (2017)
Proteasome inhibitors: antitumor effects and beyond.
A Nencioni;F Grünebach;F Patrone;A Ballestrero.
Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients.
Jan Wierecky;Martin R. Müller;Stefan Wirths;Edith Halder-Oehler.
Cancer Research (2006)
Dendritic Cell Immunogenicity Is Regulated by Peroxisome Proliferator-Activated Receptor γ
Alessio Nencioni;Frank Grünebach;Anke Zobywlaski;Claudio Denzlinger.
Journal of Immunology (2002)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: